Mobile

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men with Osteoporosis Treated with Vitamin D and Calcium 1

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-019454-41

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

2.1.1 Primary (1) Objective: To assess the effect of odanacatib 50 mg once weekly versus placebo on lumbar spine BMD over 24 months. 2) Objective: To assess the safety and tolerability of odanacatib 50 mg once weekly compared to placebo.

Critère d'inclusion

  • Men with osteoporosis

Liens